The Active Biotech Group


· Both key projects, SAIK-MS and TTS, are proceeding to Phase II
clinical trials

· Increased focus on research projects in Lund

· Financing through partnerships, possible sale of operations and
new share issue

· Operating loss of SEK -87.6 million for the period (SEK -51.5
million), adjusted pro forma year 2000 to SEK -67.8 million

· Vaccine sales of SEK 46.7 million (SEK 53.4 million)

Active Biotech plans to separate and further streamline its operations,
investing heavily in the project portfolios while focusing on a partner
strategy.

The operations of Active Biotech currently focus on the development of
pharmaceuticals and vaccines.

In Lund, the company conducts pharmaceutical research and development
and has very promising projects, particularly in the fields of MS and
cancer.